September 16, 2011
OncoTherapy Science, Inc. announced on September 15 that it has completed patient enrollment as defined in the protocol for the PII clinical trial of its angiogenesis inhibitor OCV-101, being codeveloped with Otsuka Pharmaceutical in patients with pancreatic cancer. OncoTherapy Science...read more